Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level

BACKGROUND: Omalizumab (OMA) is an effective anti-immunoglobulin E (IgE) treatment for moderate-to-severe asthma. However, predicting an individual’s response is difficult. Monitoring change of total serum IgE may be useful for predicting the response to OMA. The purpose of this study was to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bohou, Huang, Minyu, Huang, Shuyu, Zeng, Xiaoli, Yuan, Yafei, Peng, Xianru, Zhao, Wenqu, Ye, Yanmei, Yu, Changhui, Liu, Laiyu, Ou, Chunquan, Cai, Shaoxi, Zhao, Haijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797858/
https://www.ncbi.nlm.nih.gov/pubmed/33447398
http://dx.doi.org/10.21037/jtd-20-2073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797858/
https://www.ncbi.nlm.nih.gov/pubmed/33447398
http://dx.doi.org/10.21037/jtd-20-2073

Ejemplares similares